Biology of Blood and Marrow Transplantation This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Absence of Evidence for Pervasive CAR19 Driven T-Cell Lymphomagenesis Revealed By Comprehensive Genomic Profiling of an Index Tumor.
Despite the success of chimeric antigen receptor (CAR) T-cell therapies, concerns over toxicity remain. Recent reports indicate development of post-infusion T-cell lymphoma (TCL) after CAR therapy. There is minimal data regarding TCL development after commercially available CAR19 products. We analyzed 234 cases of lymphoma (189 LBCL, 20 FL, 25 MCL) treated with commercial CAR19 (100% axi-cel and brexu-cel). One patient, a 59-year-old female with CD19+/CD20+/EBV+ DLBCL, developed a post-infusion CD3+/CD4+/EBV+ T-cell lymphoma (Fig 1) diagnosed in the bone marrow (BM) on day 55 (D55). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Mark P. Hamilton, Takeshi Sugio, Troy Noordenbos, Shuyu Shi, Max Diehn, Dita Gratzinger, David B. Miklos, Ash A. Alizadeh, Zinaida Good Tags: LBA-2 Source Type: research

Reducing Ptcy Dose in Patients Receiving CAST for GvHD Prevention Results in Accelerated Engraftment at the Cost of Higher Incidence of GvHD
We previously reported excellent results of post-transplant cyclophosphamide (PTCy), abatacept (A) and a short course of tacrolimus (T) (CAST) for graft-versus-host (GvHD) prevention following peripheral blood (PB) haploidentical transplant. Mechanistic and preliminary clinical data suggest that the dose of PTCy can be decreased to diminish its toxicity while maintaining its efficacy. We sought to explore the feasibility and efficacy of reduced-dose PTCy in patients (pts) receiving CAST. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: J Andres-Suarez Londono, Kelli Cole, Frank Cirrone, Stephanie Wo, M. Maher Abdul-Hay, Jingmei Hsu, Dr. Sharon Gardner, Mohammad Abu-Zaid, Gloria Contreras Yametti, Benjamin A Levinson, Judith D Goldberg, A. Samer Al-Homsi Tags: LBA-3 Source Type: research

Use of Teduglutide in the Management of Gastrointestinal Graft-versus-Host Disease in Children and Young Adults
Gastrointestinal (GI) graft-versus-host-disease (GVHD) is a life-threatening complication of allogeneic hematopoietic stem cell transplantation (HSCT) [1]. Current treatment options include glucocorticoids, antimetabolites, and JAK1-JAK2 inhibitors [2], which are immune suppressive and carry the risk of significant adverse effects [3]. More recently, glucagon-like peptide-2 (GLP-2) has been proposed as a therapeutic target for managing GI GVHD [4]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Kristie N. Ramos, Daniel Leino, Nathan Luebbering, Michael S. Grimley, Priscila Badia, Stella M. Davies, Pooja Khandelwal Source Type: research

Phase 2 Trial of Ruxolitinib Cream for Chronic Cutaneous GvHD
Oral ruxolitinib is approved to treat aGvHD and cGvHD, while ruxolitinib cream is approved for atopic dermatitis and vitiligo. Topical corticosteroids are the mainstay of skin-directed therapy but may incompletely treat cutaneous cGvHD.We conducted a phase 2 prospective, randomized, double-blind trial evaluating the efficacy and safety of ruxolitinib 1.5% cream in patients ≥12 years old with cutaneous nonsclerotic and superficially sclerotic cGvHD with ≥2% of body surface area (BSA) affected. Patients were eligible if any systemic therapy was stable for ≥4 weeks and concurrent topical/photo- therapy was not used. (So...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Alina Markova, Esperanza B. Papadopoulos, Stephen Dusza, Veronica Rotemberg, Jelena Ostojic, Rizi Ai, Tara Maier, Mario E. Lacouture, Roni Tamari, Boglarka Gyurkocza, Brian C. Shaffer, Michael Scordo, Miguel-Angel Perales, Andrew C. Harris, Doris M. Ponce Tags: 1 Source Type: research

TSC-100 and TSC-101, TCR-T Cell Therapies That Target Residual Recipient Cells after Reduced Intensity Conditioning Transplantation, Induce Complete Donor Chimerism with Favorable Prognosis: Early Results of a Phase 1 Trial
Disease relapse after allogeneic hematopoietic cell transplantation (HCT) affects ∼40% of patients and has high mortality. A potential solution is to target antigens mismatched between transplant recipients and donors. TSC-100 and TSC-101 are allogeneic donor derived T-cell receptor-engineered T cells that target HA-1 and HA-2 hematopoietic cell antigens respectively, both pres ented on HLA-A*02:01. By choosing donors who are either HLA-A*02:01 or HA-1 negative, TSC-100 or TSC-101 selectively eliminate all residual patient hematopoietic cells post-HCT and prevent relapse (figure 1). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Monzr M. Al Malki, Alla Keyzner, Hyung C. Suh, Uday R. Popat, Nishant Dwivedi, Ashish S Kothari, Erica Buonomo, Yun Wang, Nina Abelowitz, Jim Murray, Gavin MacBeath, Debora Barton, Shrikanta Chattopadhyay, Ran Reshef Tags: 2 Source Type: research

Interim Results of a Phase I/II Trial of Intermediate-Dose Post-Transplantation Cyclophosphamide after Reduced Intensity Conditioned HLA-Mismatched Bone Marrow Transplantation for Older or Unfit Patients
High-dose post-transplantation cyclophosphamide (PTCy) is standard of care graft-versus-host disease (GVHD) prophylaxis for HLA-mismatched related (HLA-haploidentical, haplo) and HLA-mismatched unrelated (MMUD) donor hematopoietic cell transplantation (HCT). However, the optimal dosing of PTCy has not been defined. Our studies in murine HCT models support that intermediate-dose PTCy may provide superior protection against acute GVHD (aGVHD). A phase I/II study at the National Institutes of Health (NIH) of 25 mg/kg/day PTCy on days +3/+4 after haplo HCT with myeloablative conditioning (MAC) effectively prevented aGVHD, prov...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Shannon R. McCurdy, Mustafa A. Hyder, Ruby Sabina, Ashley DeVries, Kirstin Chalupa, Natasha Berryman, Jessica Bernhardt, Alison Christina Cusmano, Amy Chai, Rebecca Schwartz, Dimana Dimitrova, Kamil Rechache, Christi McKeown, Anita Stokes, Jennifer Sponau Tags: 3 Source Type: research

Triggered: How Damage Induced IL-18 Suppresses Thymus Regeneration
The thymus is highly sensitive to acute injury such as the cytoreductive conditioning given pre-hematopoietic cell transplant (HCT). The thymus is capable of a remarkable degree of regeneration, however its reparative capacity and T cell productivity decline with age leaving HCT recipients vulnerable to relapse of malignancy and opportunistic infection. Better understanding endogenous mechanisms of thymus regeneration may inform therapeutic interventions to improve T cell reconstitution in these patients. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: David Granadier, Kirsten Cooper, Lorenzo Iovino, Dante V Acenas II, Paul deRoos, Jarrod A Dudakov Tags: 4 Source Type: research

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias
For patients with relapsed/refractory large B-cell lymphomas (rrLBCL), CD19-directed chimeric antigen receptor T-cells (CAR19) improve survival compared to autologous hematopoietic cell transplantation (HCT). However, major toxicities of CAR19 therapy include prolonged cytopenias and associated infections. To better understand the impact of CAR19 on such toxicities, we studied a cohort of LBCL patients achieving durable remissions to assess immune recovery after CAR19 treatment.We first profiled bone marrow aspirates from patients requiring biopsy due to prolonged cytopenia and/or clinical concern for myeloid neoplasms. (S...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Mark P. Hamilton, Brian Sworder, Stefan Alig, Zinaida Good, Jan Boegeholz, Joseph Schroers-Martin, John Tamaresis, Mohammad Esfahani, Ying Lu, Mari Olsen, Chih Long Liu, Zachary Ehlinger, Moksha Desai, Felicia Liu-Fei, Lori S Muffly, Robert S. Negrin, Sal Tags: 5 Source Type: research

Plasma Proteome Analyses Identify Predictors of Graft Rejection Prior to Stem Cell Infusion and Support Interferon-Mediated Ferroptosis As a Novel Mechanism of Graft Rejection
No established biomarkers or effective interventions exist for graft rejection. We previously reported that CXCL9, a downstream marker of interferon, differentiates graft rejection from other complications but is only useful at the time of rejection. We hypothesized that biological differences in the host proteome exist prior to HSCT and that interferon-mediated pathways drive host elimination of donor cells during graft rejection. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Dr. Anthony Sabulski, Lucille Langenberg, Nathan Luebbering, Towia A Libermann, Simon T Dillon, Jane Koo, Kasiani C Myers, Sonata Jodele, Stella M. Davies Tags: 6 Source Type: research

B Cell Maturation Antigen (BCMA) As a Novel and Promising Target for Immunotherapy for Acute Myeloid Leukemia
Many patients with relapsed acute myeloid leukemia (AML) do not respond to current treatments, with limited available options for emerging immunotherapies such as T cell engagers (TCE) and chimeric antigen receptor (CAR) T cells. However, there has been success of CD19, CD20, and B cell maturation antigen (BCMA) directed therapies for B cell malignancies. BCMA is a protein that is preferentially expressed in mature B cells and plasma cells; its upregulation is correlated with disease burden and poor prognosis in multiple myeloma (MM). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Ashley Varkey, Mark Batistick, Manpreet Bariana, Shaina Anuncio, Elena Cassella, Johannes Zakrzewski Tags: 7 Source Type: research

Allogeneic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Features in First Complete Remission As per the International Consensus Classification (ICC) 2022: A Study from the ALWP of the EBMT
Patients (pts) formerly diagnosed as AML with myelodysplasia-related changes are currently recategorized according to their underlying genetic events in three different AML subgroups, namely AML with mutated TP53, AML with myelodysplasia-related gene mutations (MR-GM), and AML with myelodysplasia-related cytogenetic abnormalities (MR-CG) (International Consensus Classification 2022) (Arber AD, Blood 2022). The relevance of this new classification for transplantation (HSCT) outcome is largely unknown. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Arnon Nagler, Myriam Labopin, Jurjen Versluis, Jaime Sanz, Tobias Gedde-Dahl, David Burns, Nicolaas Schaap, H élène Labussière-Wallet, Peter von dem Borne, Gwendolyn Van Gorkom, Nathalie Contentin, Andreas Neubauer, Eva-Maria Wagner-Drouet, Nicolaus Kr Tags: 8 Source Type: research

Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care
The central nervous system (CNS) respresents a common site of extramedullary disease relapse in acute lymphoblastic leukmeia (ALL). CNS relapses contribute to adverse outcomes, and frequently exclude patients from participating in clinical trials. Current approved novel salvage therapies (bliantumomab and inotuzumab) have limited activity in B-ALL with CNS relapse. Brexucabtagene autoleucel (brexu-cel) was the first FDA-approved CAR T-cell product for adult patients with relapsed/refractory (r/r) B-ALL based on the ZUMA-3 study, which excluded patients with clincally evident CNS involvement. (Source: Biology of Blood and M...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Ibrahim N. Muhsen, Gregory Roloff, Noam E. Kopmar, Santiago Mercadal, Timothy E O'Connor, Kaitlyn C Dykes, Mohamed Ahmed, Simone E. Dekker, Nikeshan Jeyakumar, Muthu Veeraputhiran, Akash Mukherjee, Aaron C. Logan, Dr. Stephanie B. Tsai, Jessica T. Leonard Tags: 9 Source Type: research

Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
Somatic mutations in IDH genes are seen in ∼20% of patients with AML, with mutations in IDH2 (R172, R140) being more common (15%) than IDH1 (R132). We previously reported a higher 1-year relapse rate after HCT in patients with IDH mutations (mIDH; PMC9129101). We hypothesized that enasidenib, an IDH2 inhibitor, is well-tolerated as post-HC T maintenance, and can improve leukemia free survival (LFS) in AML patients carrying mIDH2. Here, we are reporting the final results of our completed multicenter [City of Hope (COH) and Moffitt Cancer Center] pilot trial (NCT03728335), previously reported in 2022 ASH meeting with a sho...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Amandeep Salhotra, Nelli Bejanyan, Dongyun Yang, Sally Mokhtari, Monzr M. Al Malki, Karamjeet S. Sandhu, Rawan G Faramand, Ibrahim Aldoss, Andrew S. Artz, Ahmed Aribi, Hany Elmariah, Firoozeh Sahebi, Joshua Mansour, Brian Ball, Vaibhav Agrawal, Ling Li, V Tags: 10 Source Type: research

Optimal Prognostic Threshold for Acute Myeloid Leukemia (AML) Measurable Residual Disease (MRD) Positivity By Multiparameter Flow Cytometry: A Report of 2,051 Patients from MRC/NCRI, Gimema, HOVON, and Seattle
The ELN MRD Working Party defines multiparameter flow cytometry (MFC)-based measurable residual disease (MRD) positivity for AML at the threshold of ≥0.1% of CD45-expressing cells with the target immunophenotype. This assay-agnostic approach has not been empirically validated. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Eduardo Rodr íguez-Arbolí, Megan Othus, Sylvie Freeman, Francesco Buccisano, Lok Lam Ngai, Ian Thomas, Raffaele Palmieri, Jacqueline Cloos, Sean Johnson, Elisa Meddi, Nigel H. Russell, Adriano Venditti, Patrycja Gradowska, Gert J. Ossenkoppele, Bob Lowe Tags: 11 Source Type: research

Pilot Study of Unrelated Donor (URD) Peripheral Stem Cell Transplant (PSCT) with CD45RA-Depleted Addback Following TCRab/CD19 Depletion in Pediatric Patients with Hematologic Malignancies
Ex vivo T lymphocyte depletion may decrease the risk of severe GVHD for unrelated donor SCT, but delayed immune reconstitution increases infectious risk. Addback of donor CD45RA (na ïve T cell)-depleted cells, CD45RO (memory T cells)-enriched, may accelerate immune recovery. In this pilot study we evaluated the feasibility and efficacy of CD45RA-depleted addback following TCRab/CD19-depleted unrelated donor PSCT in pediatric patients with hematologic malignancies (NCT03810196) . (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Caitlin W. Elgarten, Stephanie Heidemann, Jason L. Freedman, Stephan A. Grupp, Patricia Hankins, Stephan Kadauke, Yimei Li, Barbara McGlynn, Timothy S. Olson, Yongping Wang, Lisa Wray, Lei Wang, Alix E. Seif, Nancy J. Bunin Tags: 12 Source Type: research